TDSPharm Co

TDSPharm Co EBITDA per Employee

The EBITDA per Employee of TDSPharm Co (464280.KQ) as of Oct 25, 2026 is 41.84 M KRW. In the previous year, EBITDA per Employee was 43.89 M KRW — a change of -4.67% (lower).

EBITDA per Employee

41.84 MKRW

YoY

-4.67%

Last updated:

EBITDA per Employee of TDSPharm Co is 2025 41.84 M KRW. EBITDA per Employee of TDSPharm Co was 2024 43.89 M KRW. It decreases by -4.67% lower compared to the previous year.

The TDSPharm Co EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2021
27.73 M KRW
Jan 1, 2022
44.51 M KRW
Jan 1, 2023
57.60 M KRW
Jan 1, 2024
43.89 M KRW
Jan 1, 2025
41.84 M KRW
The TDSPharm Co EBITDA per Employee history
YEAREBITDA per EmployeeYoY
41.84 MKRW-4.67%
43.89 MKRW-23.81%
57.60 MKRW+29.42%
44.51 MKRW+60.48%
27.73 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TDSPharm Co Stock analysis

What does TDSPharm Co do? TDSPharm Co Ltd generates revenue through the manufacture and sale of synthetic drug displays and other finished drugs, as well as medical equipment sales. The company operates in the pharmaceutical manufacturing sector with a focus on synthetic drug displays and finished pharmaceutical products. Its e-commerce business complements traditional sales channels for medical equipment and pharmaceuticals. The primary customers include healthcare providers, hospitals, and medical institutions purchasing synthetic drug displays, finished drugs, and medical equipment. The company's product segments are synthetic drug displays, finished drugs, and medical equipment, with e-commerce serving as an additional sales channel for these segments. TDSPharm Co Ltd's revenue streams are derived from three core product categories: synthetic drug displays, finished drugs, and medical equipment. The company's e-commerce platform facilitates direct sales to healthcare institutions and medical facilities. The business model combines traditional manufacturing with digital sales channels, targeting healthcare providers as the main customer segment. The company's operations are centered on pharmaceutical manufacturing and medical equipment distribution, with e-commerce as a supplementary sales method. The company's primary revenue comes from the sale of synthetic drug displays and finished drugs, which are manufactured and sold directly to healthcare institutions. Medical equipment sales form a secondary revenue stream, while the e-commerce business provides an additional channel for all product categories. TDSPharm Co Ltd targets healthcare providers and medical institutions as its main customer base, with product segments focused on pharmaceutical manufacturing and medical equipment distribution. TDSPharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TDSPharm Co stock

EBITDA per Employee of TDSPharm Co is 41.84 M KRW in 2025.

EBITDA per Employee of TDSPharm Co changed from 43.89 M KRW to 41.84 M KRW, representing a -4.67% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee TDSPharm Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's TDSPharm Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — TDSPharm Co

All Key Metrics — TDSPharm Co